Camizestrant is an investigational new drug that is being evaluated to treat breast cancer.[1] It is an estrogen receptor alpha antagonist and a selective estrogen receptor degrader (SERD).[2]
References
- ^ "Camizestrant - AstraZeneca". AdisInsight. Springer Nature Switzerland AG.
- ^ Scott JS, Moss TA, Balazs A, Barlaam B, Breed J, Carbajo RJ, et al. (December 2020). "Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist". Journal of Medicinal Chemistry. 63 (23): 14530–14559. doi:10.1021/acs.jmedchem.0c01163. PMID 32910656.